Evidence map›Paper›PMID 39401129›Full record

ArticleCell transplantation

Xenogenic Engraftment of Human-Induced Pluripotent Stem Cell-Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-Pig Model.

Midori Yamasaki, Toshiyuki Maki, Taisuke Mochida, Teruki Hamada, Saori Watanabe-Matsumoto, Shuhei Konagaya, Manami Kaneko, Ryo Ito, Hikaru Ueno, Taro Toyoda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Midori YamasakiT-CiRA Discovery and Innovation, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.ORCID 0000-0001-8395-3779
Toshiyuki MakiAxcelead Drug Discovery Partners, Inc., Fujisawa, Japan.
Taisuke MochidaT-CiRA Discovery and Innovation, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Teruki HamadaAxcelead Drug Discovery Partners, Inc., Fujisawa, Japan.
Saori Watanabe-MatsumotoTakeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Japan.
Shuhei KonagayaTakeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Japan.
Manami KanekoAxcelead Drug Discovery Partners, Inc., Fujisawa, Japan.
Ryo ItoT-CiRA Discovery and Innovation, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Hikaru UenoT-CiRA Discovery and Innovation, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Taro ToyodaTakeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Japan.ORCID 0000-0002-2948-0525

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the development of cell therapy products, immunocompromised animal models closer in size to humans are valuable for enhancing the translatability of

Indexed as

Induced Pluripotent Stem CellsIslets of LangerhansIslets of Langerhans TransplantationSwine, MiniatureAnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Disease Models, AnimalHumansImmunosuppressive AgentsSwineTransplantation, HeterologousImmunosuppressive Agentscell therapyimmunosuppressantiPS cellislettype 1 diabetes

Identifiers

PMID39401129
PMCPMC11489945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.